Event Gaps: GPT-6's picks for 2026-10-13

GS

CATALYST AND FUNDAMENTALS

Observed: Goldman Sachs reported third-quarter earnings of $17.01 per share and revenue of $18.68 billion on October 13, substantially exceeding consensus expectations. Equities trading revenue rose 72% to $6.44 billion, while investment-banking fees increased 21%. These are realized business improvements rather than merely positive sentiment. The official 09:30 EDT earnings conference call has occurred. The exact initial release minute was not independently verified; event_time uses an identifiable 07:27 EDT earnings-news timestamp.

PRICE PATH AND REACTION

Before the earnings release, Goldman had consolidated after a broader September decline. The five completed sessions show a recovery from the October 7 low of $868.52, followed by the October 12 close of $893.95. The October 12 candle opened at $898.39, reached $902.29 and closed at $893.95, showing selling pressure rather than a decisive breakout.

The pre-event October 12 regular-session close was $893.95 at 2026-10-12T20:00:00Z. Its history source is https://stockanalysis.com/stocks/gs/history/. The observed quote of $904.50 is approximately 1.18% above that baseline. This appreciation has already happened and is excluded from the additional forecast move.

INTRADAY EVIDENCE

latest_price: 904.50 USD

quote_time: 2026-10-13T14:40:00Z

quote_type: regular-session, source-labelled real-time

quote_source: https://stockanalysis.com/stocks/gs/

PARTIAL SESSION: open=923.00, high_so_far=931.00, low_so_far=891.01, cumulative_volume=1889424 shares, as of 2026-10-13T14:40:00Z. The opening gap was substantial, but the retreat from $931 to $904.50 demonstrates considerable profit-taking and a long upper intraday wick. Today's partial volume must not be compared directly with a complete-session average to claim unusual participation; a matched time-of-day baseline is unavailable.

FORECAST

Direction up, with an additional 1.6% expected from the observed quote toward the end of the specified window. The thesis is that unusually strong earnings and management's favorable comments on investment-banking activity eventually attract buyers despite the initial sell-the-news reaction. The forecast does not include the opening earnings gap already realized. A recovery through $923 would strengthen the interpretation that buyers are reclaiming the initial gap.

COUNTER-EVIDENCE AND INVALIDATION

The strongest counter-evidence is the sharp reversal from the intraday $931 high, coupled with a relatively weak historical five-session trend. Sustained trading below the verified $891.01 intraday low would invalidate the anticipated recovery. Renewed concerns about interest rates, trading activity or management succession could also suppress demand.

COMPLETED DAILY OHLCV

history_source: https://stockanalysis.com/stocks/gs/history/

session_timezone: America/New_York; regular NYSE sessions; split-adjusted OHLC, not dividend-adjusted close.

daily_5d:

2026-10-06: open=901.57, high=905.94, low=896.00, close=897.18, volume=1876640

2026-10-07: open=880.85, high=888.31, low=868.52, close=887.21, volume=2357450

2026-10-08: open=880.57, high=887.49, low=876.77, close=882.59, volume=1740014

2026-10-09: open=887.68, high=899.67, low=878.86, close=895.32, volume=1779228

2026-10-12: open=898.39, high=902.29, low=887.78, close=893.95, volume=2058643

return_5d_pct: 0.05, using the 2026-10-05 close of 893.46.

high_20d: 988.28

low_20d: 868.52

avg_volume_20d: 2202720 shares

avg_dollar_volume_20d_usd: 2032263895.51

The current quote lies within the completed 20-session range. The latest completed candle does not establish an upside breakout. The bullish forecast therefore depends primarily on the new earnings information overcoming the observed intraday reversal.

WFC

CATALYST AND FUNDAMENTALS

Observed: Wells Fargo released Q3 2026 financial results on October 13. EPS of $1.87 narrowly exceeded the $1.85 consensus, but revenue of $21.87 billion missed the approximately $22.31 billion expectation. Net interest income of $12.52 billion also missed the $12.63 billion estimate. Credit-loss provisions increased to $1.03 billion from $681 million a year earlier. These are actual earnings results affecting future profit expectations. The company scheduled publication for approximately 07:00 EDT; event_time represents that officially announced approximate time.

PRICE PATH AND REACTION

Before the release, WFC had recovered from the October 1 low of $78.00 to trade above $83. The October 9 candle closed at $83.55 after reaching $84.06, but October 12 produced a failed extension: open $83.99, high $84.73 and close $83.32. That upper rejection is consistent with weakening momentum even before the earnings announcement.

The pre-event October 12 close was $83.32 at 2026-10-12T20:00:00Z, sourced from https://stockanalysis.com/stocks/wfc/history/. The observed quote of $80.89 is 2.92% below that price. This completed post-announcement repricing is not counted again in the forward expected move.

INTRADAY EVIDENCE

latest_price: 80.89 USD

quote_time: 2026-10-13T14:33:00Z

quote_type: regular-session, source-labelled real-time

quote_source: https://stockanalysis.com/stocks/wfc/

PARTIAL SESSION: open=80.57, high_so_far=83.43, low_so_far=80.31, cumulative_volume=8177858 shares, as of 2026-10-13T14:33:00Z. The recovery attempt toward $83.43 has not held, and the quote remains near the morning low. Relative intraday volume cannot be established without a clock-matched historical baseline.

FORECAST

Direction down, with an additional 1.7% decline expected from the observed quote. The underlying concern is not merely the immediate investor reaction: deposit costs, weaker net interest income and rising credit provisions could prompt downward revisions to future profitability expectations. The failure to retain the intraday recovery supports further downside, although the initial approximately 3% earnings-related decline is already reflected in the price.

COUNTER-EVIDENCE AND INVALIDATION

The strongest positive counter-evidence is continued loan growth, including 4% growth in average consumer loans and 10% growth in commercial banking loans, plus a modest EPS beat. Investors could decide that the revenue miss is temporary. A sustained recovery above the verified $83.43 intraday high would invalidate the bearish continuation thesis. A surprisingly supportive reassessment of deposit trends would be an additional fundamental invalidation.

COMPLETED DAILY OHLCV

history_source: https://stockanalysis.com/stocks/wfc/history/

session_timezone: America/New_York; regular NYSE sessions; split-adjusted OHLC.

daily_5d:

2026-10-06: open=81.85, high=81.98, low=81.08, close=81.51, volume=12150085

2026-10-07: open=80.48, high=80.82, low=79.07, close=80.26, volume=13541257

2026-10-08: open=79.90, high=82.17, low=79.70, close=82.03, volume=16615569

2026-10-09: open=81.95, high=84.06, low=81.62, close=83.55, volume=22314720

2026-10-12: open=83.99, high=84.73, low=83.02, close=83.32, volume=14225293

return_5d_pct: 2.31, using the 2026-10-05 close of 81.44.

high_20d: 91.99

low_20d: 78.00

avg_volume_20d: 14353883.35 shares

avg_dollar_volume_20d_usd: 1193142155.01

The completed five-session return remains positive, making the bearish call a reversal of the recent recovery rather than an extension of an established five-day decline. Today's disappointing earnings reaction supports that reversal, but the stock has not yet broken the completed 20-session low.

UNH

CATALYST AND FUNDAMENTALS

Observed: UnitedHealth reported third-quarter adjusted EPS of $4.69 and revenue of approximately $112.7 billion, exceeding consensus expectations. Its medical-care ratio improved to 88.4%, and management raised full-year adjusted EPS guidance to at least $20.50. These improvements provide a genuine fundamental argument for recovery. However, substantial membership losses, including roughly 935,000 Medicare Advantage members, and ongoing uncertainty around medical costs complicate the turnaround thesis. The results were released before the market opened, but the exact release minute was not independently verified. event_time uses the officially scheduled 08:00 EDT earnings conference call.

PRICE PATH AND REACTION

During the completed October 6-12 sessions, UNH traded without a decisive trend. The October 9 candle showed a large upper wick, reaching $387.52 but closing at $379.30. On October 12 the stock opened at $382.98, which also became its session high, and closed at $378.52. Both candles suggest supply above approximately $380.

The pre-event October 12 close was $378.52 at 2026-10-12T20:00:00Z. At the observed $376.01 quote, the stock was approximately 0.66% below that pre-event baseline. The morning earnings gap and subsequent reversal have already occurred and are not part of the remaining forecast.

INTRADAY EVIDENCE

latest_price: 376.01 USD

quote_time: 2026-10-13T14:32:00Z

quote_type: regular-session, source-labelled real-time

quote_source: https://stockanalysis.com/stocks/unh/

PARTIAL SESSION: open=397.63, high_so_far=399.88, low_so_far=372.80, cumulative_volume=5158130 shares, as of 2026-10-13T14:32:00Z. The advance above the completed 20-session high of $387.52 failed dramatically. The stock reversed from almost $400 to below the prior close, forming a pronounced upper intraday wick. Partial volume cannot be directly assessed against completed-session average volume without a same-time baseline.

FORECAST

Direction down, expecting an additional 1.9% decline from the observed quote over the specified window. Despite objectively better reported earnings, the rejection of the opening gap is unusually forceful and implies that investors may be using positive news to reduce exposure. The market may remain focused on membership attrition, reimbursement uncertainty and the quality of the medical-cost improvement. This is a bearish sentiment and price-action inference, not a claim that reported operating fundamentals deteriorated.

COUNTER-EVIDENCE AND INVALIDATION

The strongest counter-evidence is the actual improvement in the medical-cost ratio and higher full-year guidance. The decline may represent temporary profit-taking rather than a durable reassessment. A sustained recovery above the verified $387.52 completed-session resistance, particularly if supported by continued guidance confidence, would invalidate the short-term bearish thesis. A further recovery toward the observed $397.63 opening price would provide stronger contradictory evidence.

COMPLETED DAILY OHLCV

history_source: https://stockanalysis.com/stocks/unh/history/

session_timezone: America/New_York; regular NYSE sessions; split-adjusted OHLC.

daily_5d:

2026-10-06: open=379.03, high=380.41, low=373.70, close=376.32, volume=4654395

2026-10-07: open=375.92, high=383.48, low=372.01, close=375.98, volume=5486758

2026-10-08: open=375.38, high=376.45, low=368.50, close=370.95, volume=7113981

2026-10-09: open=373.94, high=387.52, low=373.02, close=379.30, volume=7437703

2026-10-12: open=382.98, high=382.98, low=373.67, close=378.52, volume=5831543

return_5d_pct: -0.02, using the 2026-10-05 close of 378.58.

high_20d: 387.52

low_20d: 362.60

avg_volume_20d: 4870108.85 shares

avg_dollar_volume_20d_usd: 1826228299.66

Historical performance was essentially flat over five sessions. The primary bearish evidence therefore comes from the completed sessions' upper-wick behavior and today's failed earnings breakout, rather than from a persistent prior decline. A strong rebound remains a material risk.

MU

CATALYST AND FUNDAMENTALS

Observed: Chinese memory manufacturer ChangXin Memory Technologies disclosed progress in a high-density 4F-square DRAM cell architecture, creating concern about future competition for Micron. A South China Morning Post report was published October 12 at 08:30 Hong Kong time and documented the development. The exact time of the original industry presentation, which occurred over the preceding weekend, was not verified; event_time represents that dated news-evidence timestamp. CXMT's planned server-memory product launch by the end of 2026 remains a future intention rather than a demonstrated commercial outcome. The competitive concern is material, but the speed and economic impact of any production-scale adoption remain uncertain.

Observed countervailing fundamentals include Micron's additional $33 billion repurchase authorization, taking its total authorization to approximately $35 billion. This does not guarantee immediate purchases or establish a price floor, but it offers a potential fundamental counterweight to the negative competitive news.

PRICE PATH AND REACTION

Micron was already weakening before the CXMT story became prominent. The October 7 session rallied sharply, reaching $1089.22 and closing at $1088.00, but October 8 produced a bearish reversal with a $1035.84 close. October 9 opened at its high of $1054.17 and closed at $1029.00, followed by another decline to $989.04 on October 12. The sequence shows downward pressure and a failure to sustain earlier rebounds.

The October 9 close of $1029.00 at 2026-10-09T20:00:00Z provides a pre-October-12-news reference. The observed $949.00 quote represents a decline of approximately 7.77% from that baseline. Not all of this decline can be attributed solely to CXMT, because the semiconductor sector was already weak. The decline already observed is not the predicted future opportunity.

INTRADAY EVIDENCE

latest_price: 949.00 USD

quote_time: 2026-10-13T14:41:00Z

quote_type: regular-session, source-labelled real-time

quote_source: https://stockanalysis.com/stocks/mu/

PARTIAL SESSION: open=934.07, high_so_far=952.62, low_so_far=929.03, cumulative_volume=11145207 shares, as of 2026-10-13T14:41:00Z. Although the stock is markedly below the previous close, the latest quote exceeds the session open and lies near the intraday high. This provides preliminary evidence of buying after the opening decline. Without clock-matched historical volume, unusual relative intraday participation cannot be established.

FORECAST

Direction up, expecting an additional 2.2% recovery from the observed quote through the target window. This is explicitly a contrarian reversal forecast, not an assertion that the longer decline has ended. The proposed edge is that the market may be discounting a future Chinese competitive threat before production economics and actual market penetration are known. A developing intraday recovery and significant buyback authorization provide possible support. The forecast does not attempt to recapture the entire recent selloff.

COUNTER-EVIDENCE AND INVALIDATION

The strongest counter-evidence is sustained multi-session selling, broad weakness across global memory-chip manufacturers and the genuine possibility that CXMT eventually reduces incumbents' pricing power. A renewed fall below today's verified $929.03 low would undermine the immediate recovery hypothesis; a subsequent move below the completed-session 20-day low of $917.64 would be stronger bearish confirmation. Further evidence of near-term CXMT commercial readiness would also invalidate the fundamental basis for expecting a sentiment reversal.

COMPLETED DAILY OHLCV

history_source: https://stockanalysis.com/stocks/mu/history/

session_timezone: America/New_York; regular Nasdaq sessions; split-adjusted OHLC.

daily_5d:

2026-10-06: open=1064.48, high=1074.31, low=1045.26, close=1045.56, volume=20765103

2026-10-07: open=1017.37, high=1089.22, low=1011.42, close=1088.00, volume=30131770

2026-10-08: open=1077.50, high=1088.50, low=1032.10, close=1035.84, volume=28908534

2026-10-09: open=1054.17, high=1054.17, low=1017.00, close=1029.00, volume=19720701

2026-10-12: open=1002.45, high=1002.67, low=978.50, close=989.04, volume=23519988

return_5d_pct: -7.04, using the 2026-10-05 close of 1063.96.

high_20d: 1108.72

low_20d: 917.64

avg_volume_20d: 25394489.15 shares

avg_dollar_volume_20d_usd: 26560723694.61

The completed five-session structure strongly favors downside continuation, making this the least technically aligned forecast among the selections. The reversal hypothesis depends on today's observed recovery from the opening decline and the distinction between long-term competitive risk and immediately established business damage. Confidence is accordingly reduced.

SNDX

CATALYST AND FUNDAMENTALS

Observed: Syndax Pharmaceuticals announced on October 12 at 16:01 EDT that the Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint, the annualized rate of decline in forced vital capacity. Management indicated that it would discontinue development of axatilimab for this indication. This is a material negative clinical result and removes a potential commercial expansion opportunity. The result does not revoke axatilimab's existing approval in chronic graft-versus-host disease, and the company retains other commercial and development programs.

Analysts have reacted differently. BofA reduced its target to $23 from $26, while Citi described the selloff as potentially creating an attractive entry point. These conflicting interpretations raise uncertainty about whether the valuation impact has already been fully discounted.

PRICE PATH AND REACTION

The stock had already shown weakness before the trial result. It closed at $17.37 on October 6, $17.03 on October 7, $16.90 on October 8 and $16.99 on October 9. October 12 opened at $16.88, reached $16.95 and closed at $16.55. The closing position near the session low, combined with the recent decline, indicates limited buying conviction before the announcement.

The pre-event October 12 close was $16.55 at 2026-10-12T20:00:00Z, immediately preceding the 16:01 EDT announcement. At the observed $13.78 quote, the price was already approximately 16.74% below the pre-event close. That adverse adjustment is realized and is explicitly excluded from the additional forecast decline.

INTRADAY EVIDENCE

latest_price: 13.78 USD

quote_time: 2026-10-13T14:22:00Z

quote_type: regular-session, source-labelled real-time

quote_source: https://stockanalysis.com/stocks/sndx/

PARTIAL SESSION: open=14.61, high_so_far=14.74, low_so_far=13.49, cumulative_volume=2521555 shares, as of 2026-10-13T14:22:00Z. The opening gap was strongly negative and the stock subsequently traded below its opening price. It has recovered modestly from the observed intraday low, so downside continuation is not assured. Relative intraday volume cannot be reliably classified without a clock-matched historical baseline.

FORECAST

Direction down, expecting an additional 3.5% decline from the observed quote over the specified window. The anticipated second leg lower reflects the possibility of further institutional reassessment of axatilimab's addressable market, commercialization value and the probability-adjusted pipeline. The removal of an entire indication is a fundamental setback rather than purely a technical shock. Nevertheless, much of the obvious negative information is already reflected in the approximately 17% selloff, and that limits conviction in additional downside.

COUNTER-EVIDENCE AND INVALIDATION

The strongest counter-evidence is that Syndax retains approved therapies and ongoing studies, while some analysts regard the selloff as excessive. A sustained recovery above the verified $14.74 intraday high would invalidate the immediate bearish continuation hypothesis. A substantive management clarification showing that the failed indication represented only a minor share of anticipated valuation would also weaken the thesis. The risk of a sharp short-covering or bargain-hunting rebound is elevated after the large observed decline.

COMPLETED DAILY OHLCV

history_source: https://stockanalysis.com/stocks/sndx/history/

session_timezone: America/New_York; regular Nasdaq sessions; split-adjusted OHLC.

daily_5d:

2026-10-06: open=17.99, high=18.19, low=16.85, close=17.37, volume=1126134

2026-10-07: open=17.17, high=17.70, low=17.03, close=17.03, volume=1588507

2026-10-08: open=16.90, high=17.29, low=16.39, close=16.90, volume=2142238

2026-10-09: open=16.91, high=17.42, low=16.78, close=16.99, volume=1453152

2026-10-12: open=16.88, high=16.95, low=16.37, close=16.55, volume=1588277

return_5d_pct: -7.18, using the 2026-10-05 close of 17.83.

high_20d: 18.94

low_20d: 16.37

avg_volume_20d: 1931827.55 shares

avg_dollar_volume_20d_usd: 34159888.87

The observed $13.78 intraday price is below the completed 20-session low of $16.37, establishing a post-event breakdown. However, historical average dollar liquidity is only moderately above the required $20 million threshold. Wider spreads and sharper reversals than those of large-cap stocks are plausible. The reported market capitalization of approximately $1.23 billion remains above the eligibility floor at the observed quote.